A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
Steffan W. Wolfe, BA
Advertisement
Articles by Steffan W. Wolfe, BA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose
3
United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF
4
HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD
5